J. Mills

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Nicholas D. Adams, K. Swinger, R. Prinjha, 2019, Cancer cell.

Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Tim J. Wigle, T. Riera, R. Copeland, 2016, ACS medicinal chemistry letters.

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

Jodi Gureasko, W. Janzen, T. Riera, 2018, PloS one.

AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer an

S. Barry, G. Shapiro, J. Bono, 2016 .

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Nicholas D. Adams, K. Swinger, R. Prinjha, 2019, Cancer cell.